Risks of estrogen plus progestin therapy: A sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial

Climacteric

Volumn 6, Issue 4, 2003, Pages 302-313

  Shapiro, S ^a  

^a Columbia University ^*  (United States)

Author keywords

Breast cancer; Coronary heart disease; Detection bias; Hormone replacement therapy; Stroke; Venous thromboembolism

Indexed keywords

ESTROGEN; GESTAGEN; PLACEBO;

ARTICLE; BREAST CARCINOMA; CANCER INCIDENCE; CANCER RISK; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DOUBLE BLIND PROCEDURE; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MEDICAL RESEARCH; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; STROKE;

EID: 1242348168     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.1080/713605431     Document Type: Article

References (12)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-33
2. Blanc B, Cravello L, Micheletti M-C, D'Eriole C, Zaterian M. Continuous hormone therapy for menopause combining nomegestrol and gel, patch, or oral estrogen: a comparison of amenorrhea rates. Clin Ther 1998;20:901-12
3. Notelowitz M, Mattox JH. Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17β-estradiol. Menopause 2000;3:310-17
4. The Writing Group for the PEPI trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. J Am Med Assoc 1996;275:370-5
5. Skegg DCG. Potential bias in case-control studies of oral contraceptives and breast cancer. Am J Epidemiol 1988;127:205-12
6. Shapiro S, Venet W, Strax P, et al. Ten- to fourteen-year effect of screening on breast cancer mortality. J Natl Cancer Inst 1982;69:349-55
7. Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen-progestin on mammographic parenchymal density. Ann Intern Med 1999;130:262-9
8. Calvin FN, Mello-Thoms C, Kandel HL, Weinstein SP. Time course of perception and decision making during mammographic interpretation. Am J Roentgenol 2002;179:917-23
9. Castellsague J, Perez Gutthan S, Garcia Rodriguez LA. Recent epidemiological studies of the association between hormone replacement therapy and venous thrombosis. A review. Drug Safety 1998;18:117-23
10. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases the risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000;132:689-96
11. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The Women's Health Initiative randomized controlled trial. J Am Med Assoc 2003;289:3243-53
12. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34